CELLECTIS - ADR (CLLS:NASDAQ)
$1.26 0.01 (0.8%)
Analysed CELLECTIS - ADR (CLLS:NASDAQ) News Sources
Monthly information on share capital and company voting rights
06-10-2026
yahoo.com
European Equities Traded in US as ADRs Fall in Wednesday Trading
07-10-2026
yahoo.com
European Equities Traded in US as ADRs Fall in Thursday Trading
08-10-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
18-09-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
22-09-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
06-10-2026
yahoo.com
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
15-09-2026
stocktwits.com
Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
17-09-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
30-09-2026
yahoo.com
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
01-10-2026
marketbeat.com
What is the current price of CELLECTIS - ADR (CLLS:NASDAQ)?
The current price of CELLECTIS - ADR (CLLS:NASDAQ) is $1.26.
CELLECTIS - ADR (CLLS:NASDAQ) absolute price change since previous trading day?
The absolute price change of CELLECTIS - ADR (CLLS:NASDAQ) since the previous trading day is $0.01.
CELLECTIS - ADR (CLLS:NASDAQ) percentage price change since previous trading day?
The percentage price change of CELLECTIS - ADR (CLLS:NASDAQ) since the previous trading day is 0.8%.
What is the most recent average sentiment score for CELLECTIS - ADR (CLLS:NASDAQ)?
The most recent average sentiment score for CELLECTIS - ADR (CLLS:NASDAQ) is 35 out of 100.
What is the most recent average sentiment for CELLECTIS - ADR (CLLS:NASDAQ)?
The most recent sentiment for CELLECTIS - ADR (CLLS:NASDAQ) is .
SEC-8K** Filing Available For CELLECTIS - ADR (CLLS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.